Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Peter, Stephens"'
Autor:
Amit Bahl, William Wilson, Jessica Ball, Emily Renninson, Sidharth Dubey, Alicia Bravo, Emily Foulstone, Saiqa Spensley, Rebecca Bowen, Janine Mansi, Simon Waters, Pippa Riddle, Duncan Wheatley, Peter Stephens, Pavel Bezecny, Srinivasan Madhusudan, Mark Verrill, Jeremy Braybrooke, Charles Comins, Vivek Mohan, Abigail Gee, Hannah Kirk, Alison Markham, Heidi Evans, Eve Watson, Mark Callaway, Sylvia Pearson, Allan Hackshaw, Mark Churn
Publikováno v:
Breast, Vol 66, Iss , Pp 69-76 (2022)
Background: Paclitaxel is commonly used as first-line chemotherapy for HER2-negative metastatic breast cancer (MBC) patients. However, with response rates of 21.5–53.7% and significant risk of peripheral neuropathy, there is need for better chemoth
Externí odkaz:
https://doaj.org/article/82333b9202654f2ab93e6857aabae51e
Publikováno v:
Malaria Journal, Vol 17, Iss 1, Pp 1-14 (2018)
Abstract Background The steady supply of quality, affordable medicines is a pillar of a functioning health system. In addition to the public sector, the private, mission and not-for-profit sectors often serve a large part of the population in Africa.
Externí odkaz:
https://doaj.org/article/02953c8cb87043b2a04c2233c5ee3d75
Autor:
Andréa Dâmaso Bertoldi, Anita K. Wagner, Isabel Cristina Martins Emmerick, Luisa Arueira Chaves, Peter Stephens, Dennis Ross-Degnan
Publikováno v:
Journal of Pharmaceutical Policy and Practice, Vol 12, Iss 1 (2019)
Objectives To describe changes in the private market for selected originators, branded generics (‘similares’), and generic products during the 10 years following passage of the Brazilian Generics Law. Methods We analyzed longitudinal data collect
Externí odkaz:
https://doaj.org/article/b20e9f0d7311470cb31cb11348f21399
Autor:
Matthew C Winter, Daniel Rea, Jacinta Abraham, Olga Oikonomidou, Iain R. Macpherson, David Cameron, Jeremy P Braybrooke, Sarah Kernaghan, Andrew M Wardley, Heidrun Gevensleben, Laura Moretti, Mark Tuthill, Katrina Randle, Peter Stephens, A Ring, Mike Hubank, Judith M Bliss, Rebecca Roylance, Abeer M Shaaban, Hannah Bye, Lucy Kilburn, Sue Martin, B Kingston, Katie Wilkinson, Nicholas C. Turner, Claire Snowdon, Ros Cutts, Richard D. Baird
Publikováno v:
C Turner, N, Kingston, B, S Kilburn, L, Kernaghan, S, M Wardley, A, R Macpherson, I, D Baird, R, Roylance, R, Stephens, P, Oikonomidou, O, P Braybrooke, J, Tuthill, M, Abraham, J, C Winter, M, Bye, H, Hubank, M, Gevensleben, H, Cutts, R, Snowdon, C, Rea, D, Cameron, D A, Shaaban, A, Randle, K, Martin, S, Wilkinson, K, Moretti, L, Bliss, J M & Ring, A 2020, ' Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial ', The Lancet Oncology, vol. 21, no. 10, pp. 1296-1308 . https://doi.org/10.1016/S1470-2045(20)30444-7
BACKGROUND: Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biopsy. We aimed to assess the accuracy of ctDNA testing in advanced breast cancer and
Publikováno v:
Molecules; Volume 27; Issue 5; Pages: 1504
The increase in the number of bacteria that are resistant to multiple antibiotics poses a serious clinical problem that threatens the health of humans worldwide. Nadifloxacin (1) is a highly potent antibacterial agent with broad-spectrum activity. Ho
Publikováno v:
Bulletin of the World Health Organization
To assess sales of anti-cancer medicines in the 2017 World Health Organization'sWe extracted sales volume data for 39 anti-cancer medicines from the IQVIA database. We divided the total quantity sold by the reference defined daily dose to estimate th
Autor:
Matthew C Winter, Daniel Rea, Peter Stephens, Rebecca Roylance, Nicholas C. Turner, Jeremy P Braybrooke, Hannah Bye, Lucy Kilburn, Claire Snowdon, Sarah Kernaghan, Iain R. Macpherson, Judith M Bliss, Richard D. Baird, Mike Hubank, Abeer M Shaaban, Andrew M Wardley, Katie Wilkinson, Alistair Ring, Mark Tuthill, Jacinta Abraham, Katrina Randle, Belinda Kingston, David Cameron, Olga Oikonomidou, Laura Moretti
Publikováno v:
Cancer Research. 80:GS3-06
Background: Circulating tumour DNA (ctDNA) testing may provide a more current assessment of the genetic profile of advanced breast cancer (BC) compared with analysis of the primary tumour, with repeat advanced disease biopsy conducted infrequently in
Autor:
Peter Stephens, Belinda Kingston, Andrew M Wardley, Nicholas C. Turner, Iain R. Macpherson, Rebecca Roylance, Judith M Bliss, Jeremy P Braybrooke, Richard D. Baird, Sarah Kernaghan, Mark Tuthill, Olga Oikonomidou, Jacinta Abraham, Lucy Kilburn, Katie Wilkinson, Matthew C Winter, Alistair Ring
Publikováno v:
Cancer Research. 80:P1-19
Background: Activation of the AKT pathway can result from diverse rare genetic events, including mutation of AKT1, AKT2/3 E17K, and through inactivating mutation or homozygous deletion of PTEN. AKT1 mutations and genetic loss of PTEN are associated w
Autor:
Iain R. Macpherson, Alistair Ring, Andrew M Wardley, Katie Wilkinson, Lucy Kilburn, Peter Stephens, Rebecca Roylance, Mark Tuthill, Olga Oikonomidou, Matthew C Winter, Nicholas C. Turner, Richard D. Baird, Jacinta Abraham, Belinda Kingston, Jeremy P Braybrooke, Sarah Kernaghan, Judith M Bliss
Publikováno v:
Cancer Research. 80:P1-19
Background: HER2 mutations occur in approximately 3% of HER2 non-amplified cancers and include missense substitutions and indels within the tyrosine kinase domain resulting in oncogenic HER2 activation. Neratinib, an irreversible EGFR, HER2 and ERBB4
Autor:
Iain R. Macpherson, Matthew C Winter, Mark Tuthill, Rebecca Roylance, Alistair Ring, Peter Stephens, Belinda Kingston, Andrew M Wardley, Katie Wilkinson, Olga Oikonomidou, Nicholas C. Turner, Jacinta Abraham, Lucy Kilburn, Jeremy P Braybrooke, Sarah Kernaghan, Judith M Bliss, Richard D. Baird
Publikováno v:
Cancer Research. 80:P1-19
Background: AKT1 mutation occurs in approximately 3% of breast cancer (BC), enriched in advanced BC. The AKT1 E17K mutation results in constitutive activation of AKT1, associated with sensitivity to AKT inhibitor capivasertib in pre-clinical models,